Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Expands Its Presence In Urology With Myrbetriq Approval

Executive Summary

Astellas is tasked with introducing a new product into the already crowded overactive bladder market now that it has gained approval for the beta-3 antagonist mirabegron in the U.S.

You may also be interested in...



Astellas U.S. Priorities Are Oncology Expansion, BD – President Robinson

Astellas Pharma US expects oncology will account for 40% of sales in three years, becoming its top business segment – significant growth for a company that just four years ago had no commercial presence in oncology. The plans rely heavily on Xtandi, suggesting it might be time to ramp up business development activity.

Botox Adds Therapeutic Indication For Idiopathic Overactive Bladder

The FDA approval for idiopathic OAB follows a narrower indication for OAB related to neurological diseases such as multiple sclerosis or spinal cord injury.

Allergan Seeks To Extend Botox Use To Overactive Bladder

During an R&D day March 28, Allergan highlighted its growth strategy for Botox, which includes expansion into new indications like overactive bladder; the company submitted an sBLA for the indication.

Topics

Related Companies

UsernamePublicRestriction

Register

PS054564

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel